Axxam is an innovative Partner Research Organization (iPRO). We are a leading provider of integrated discovery services across Life Sciences industries including: pharmaceuticals, crop protection, animal health, cosmetics, fragrances, food and beverages. We have consolidated expertise across a broad range of discovery disciplines and innovative technologies including: assay development, high-throughput screening of both the Axxam high quality compound collections (synthetic and natural)  or those provided by our clients, compound management, hit identification and hit validation.  Our performance-driven approach has been recognized by our clients as key to the success for their discovery programs. Axxam is also engaged in alliance-based research towards innovative small molecule therapies for diseases with a high unmet medical need. Axxam’s business terms are flexible, ranging from fee-for-service to risk-sharing deal structures. 

Axxam and Promega announce agreement to develop smart assays for drug discovery services

Axxam and Promega announced today formalization of an agreement that will offer world-class early-stage drug discovery services for different classes of targets and cellular pathways. Global clients...

SLAS Europe
Brussels, Belgium

22-26 May 2023
Brussels, Belgium

EWDSy
Siena, Italy

21-24 May 2023
Siena, Italy

Kinase 2023
SCI/RSC Symposium

9-10 May 2023
London, UK

Swiss Biotech Days
Basel, Switzerland

24-25 April 2023
Basel, Switzerland

AD/PD 2023
Gothenburg, Sweden

28 March – 1 April 2023
Gothenburg, Sweden

Subscribe to Our Newsletter

Follow us on